Evidence map›Paper›PMID 27777980›Full record

ArticleJCI insight2016

Ly6C

Jiangao Zhu, Huiyao Chen, Xiaopei Huang, Songfu Jiang, Yiping Yang

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Interferon-γ-Producing CD4Frontiers in immunology · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Jiangao ZhuDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and.
Huiyao ChenDepartment of Hematology,First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaopei HuangDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and.
Songfu JiangDepartment of Hematology,First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yiping YangDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and.
Cellular Therapeutics (United Kingdom) · GB

Funding

Novel Strategies for Cancer Immunotherapy in Stem Cell TransplantR01CA136934 · NCI · OHIO STATE UNIVERSITY · PI YANG, YIPING · 2009 to 2018
$3.4M
T Memory Stem Cells in CancerR01CA193167 · NCI · OHIO STATE UNIVERSITY · PI YANG, YIPING · 2016 to 2020
$2.2M
Role of inflammation in cancer progressionR21CA186973 · NCI · DUKE UNIVERSITY · PI YANG, YIPING · 2014 to 2015
$378k
NCI NIH HHS R01 CA136934NCI NIH HHS R01 CA193167NCI NIH HHS R21 CA186973
6 · The paper itself

Abstract

Viral hepatitis remains a global health challenge despite recent progress in the development of more effective therapies. Although virus-specific CD8

Indexed as

AnimalsB7-H1 AntigenDisease Models, AnimalHepatitis, Viral, AnimalLiverMiceMice, Inbred C57BLMice, TransgenicMonocytesNitric OxideNitric Oxide Synthase Type IIProgrammed Cell Death 1 ReceptorReceptors, CCR2T-LymphocytesB7-H1 AntigenCcr2 protein, mouseCd274 protein, mouseNitric OxideNitric Oxide Synthase Type IINos2 protein, mousePdcd1 protein, mouseProgrammed Cell Death 1 ReceptorReceptors, CCR2

Identifiers

PMID27777980
PMCPMC5070953
OpenAlexW2532654161

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.